GRAIL Q3: Galleri Revenue Up 14% to $37.3M, Net Loss Widens to $103.6M
GRAL has more than doubled off its 52-week low of $41.5 on elevated volume (1.9× avg).
Summary
GRAIL's Q3 showed Galleri volume up 24% but pricing down 9% on a September promotion, widening the net loss to $103.6M and Adjusted EBITDA loss to $92.6M. Cash plus marketable securities of $788.7M funds roughly two more years at the current burn rate.
Key Events · Earnings and Guidance · GRAL
-
Galleri Volume Up, Pricing Down
Screening revenue rose 14% to $37.3M on a 24% increase in Galleri sales volume, offset by a 9% decline in average selling price driven by the promotional pricing launched in September 2026.
-
Losses and Cash Burn Widen
Net loss widened to $103.6M from $89.0M and Adjusted EBITDA loss to $92.6M from $71.7M; operating cash use was $242.5M for the nine months versus $235.2M a year earlier.
-
Liquidity of $788.7M
Cash and equivalents of $29.0M plus $759.7M of short-term marketable securities; management says this funds at least the next 12 months, and $189.3M remains available under the ATM program.
-
New Patent Suit Filed
Clinical Genomics sued GRAIL on September 11, 2026 in the District of Delaware, alleging Galleri infringes two U.S. patents on methylation-based detection; exposure is not estimable.
Analysis · GRAL · Industrial Applications And Services
Galleri volume is growing, but the economics are deteriorating: a September promotional price cut pushed average selling price down 9%, so screening revenue rose only 14% while cost of screening revenue jumped 38% and sales and marketing rose 63%. The company burned $242.5M of operating cash in nine months and now holds $29.0M of cash plus $759.7M of treasury securities — roughly two years of runway at the current burn, but the widening losses mean another raise is likely before the FDA decides on the PMA, now expected in early Q1 2027. A new patent suit over methylation detection adds a fresh legal overhang on top of the existing NHS-Galleri securities class action.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRAL was trading at $119.13 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $41.50 to $166.48. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.